-
-
Credits Available
Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™
Nurses - 1.00 ANCC Contact Hour(s) (0 contact hours are in the area of pharmacology)
Pharmacists - 1.00 Knowledge-based ACPE (0.100 CEUs)
You Are Eligible For
Target Audience and Goal Statement
This activity is intended for psychiatrists, primary care physicians (PCPs), pediatricians, nurse practitioners (NPs), physician
assistants (PAs), nurses, and pharmacists, and other clinicians who care for patients with ADHD.
The goal of this activity is for learners to be better able to differentiate ADHD from other psychiatric disorders, describe
the latest clinical data on new medications, and individualize treatment approaches for ADHD with a focus on nonstimulants
in the adult population.
Upon completion of this activity, participants will:
- Have increased knowledge regarding the
- Considerations of comorbidities when selecting treatment for adult patients with ADHD
- Have greater competence related to
- Diagnosis of ADHD
- Using a nonstimulant medication in appropriate patients with ADHD
- Demonstrate greater confidence in their ability to
- Individualize management approaches for patients with ADHD based on specific patient characteristics
Disclosures
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships
with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary
business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed
below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
Moderator

-
Ann Childress, MD
Adjunct Faculty, UNLV and Touro University of Nevada
President, Center for Psychiatry and Behavioral Medicine, Inc.
President, American Professional Society for ADHD and Related Disorders
Las Vegas, Nevada
Disclosures
Ann Childress, MD, has the following relevant financial relationships:
Consultant or advisor for: Adlon Therapeutics L.P.; Akili Interactive Labs, Inc.; Aytu (NEOS Therapeutics, Inc.); Cingulate;
Corium International, Inc.; Lumos Pharma; Noven Pharmaceuticals, Inc.; Otsuka Pharmaceutical Co., Ltd.; Purdue Pharma L.P.;
Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Sky; Tris Pharma, Inc.; Tulex Pharmaceuticals.
Speaker or member of speakers bureau for: Corium International, Inc.; Ironshore Pharmaceuticals, Inc.; Supernus Pharmaceuticals,
Inc.; Takeda Pharmaceutical Company Limited; Tris Pharma, Inc.
Research funding from: Allergan, Inc.; Akili Interactive Labs, Inc.; Cingulate; Otsuka Pharmaceutical Co., Ltd.; Lumos Pharma;
Purdue Pharma L.P.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited (Shire)
Contracted researcher for: Allergan, Inc.; Akili Interactive Labs, Inc.; Cingulate; Otsuka Pharmaceutical Co., Ltd.; Lumos
Pharma; Purdue Pharma L.P.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited
(Shire)
Faculty

-
Gregory W. Mattingly, MD
Associate Clinical Professor
Washington University School of Medicine
President, Midwest Research Group
President Elect, American Professional Society for ADHD and Related Disorders
St. Louis, Missouri
Disclosures
Gregory W. Mattingly, MD, has the following relevant financial relationships:
Consultant or advisor for: AbbVie Inc.; ACADIA Pharmaceuticals Inc.; Alkermes, Inc.; Axsome Therapeutics, Inc.; Corium International,
Inc.; Eisai Inc.; Intra-Cellular Therapies, Inc.; Ironshore Pharmaceuticals, Inc.; Janssen Pharmaceuticals; Lundbeck, Inc.;
NEOS Therapeutics, Inc.; Neurocrine Biosciences, Inc.; Noven Pharmaceuticals, Inc.; Otsuka Pharmaceutical Co., Ltd.; Redax;
Roche; Rhodes Pharmaceuticals L.P.; Sage Therapeutics, Inc.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.;
Takeda Pharmaceutical Company Limited; Teva Pharmaceuticals USA; Tris Pharma, Inc.
Research funding from: AbbVie Inc.; Alkermes, Inc.; Corium International, Inc.; Eisai Inc.; Intra-Cellular Therapies, Inc.;
Ironshore Pharmaceuticals, Inc.; Janssen Pharmaceuticals; Lundbeck, Inc.; Neurocrine Biosciences, Inc.; Noven Pharmaceuticals,
Inc.; Otsuka Pharmaceutical Co., Ltd.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceutical
Company Limited.; Tris Pharma, Inc.
Contracted researcher for: AbbVie Inc.; ACADIA Pharmaceuticals Inc.; Akili Interactive Labs, Inc.; Alkermes, Inc.; Axsome
Therapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Emalex Biosciences; Idorsia Pharmaceuticals, Ltd.; Janssen
Pharmaceuticals; Karuna Therapeutics; Lumos Labs; Medgenics; NLS-1 Pharma AG; Redax; Relmada Therapeutics, Inc.; Roche; Sage
Therapeutics, Inc.; Sirtsei Pharmaceuticals Inc.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceutical
Company Limited.; Teva Pharmaceuticals USA.
Editor
Compliance Reviewer/Nurse Planner
Peer Reviewer
This activity has been peer reviewed and the reviewer has no relevant financial relationships.
Accreditation Statements
Developed through a partnership between Medscape Education, APSARD, and Amedco.
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and American Professional
Society of ADHD and Related Disorders (APSARD). Amedco LLC is jointly accredited by the Accreditation Council for Continuing
Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing
Center (ANCC), to provide continuing education for the healthcare team.
For Pharmacists
-
Amedco LLC designates this continuing education activity for a maximum of 1.0 knowledge-based CPE contact hours (Universal
Activity Number: JA4008163-9999-23-043-H01-P).
NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate
within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.
Contact This Provider
For questions regarding the content of this activity, contact the
accredited provider for this CME/CE activity noted above. For technical
assistance, contact [email protected]
Instructions for Participation and Credit
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.
Follow these steps to earn CME/CE credit*:
- Read about the target audience, learning objectives, and author disclosures.
- Study the educational content online or print it out.
- Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated
at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.